HealthTree recruits over 1,000 participants for study on impact of COVID-19 on MM

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A total of 1,066 patients have joined a HealthTree observational study on COVID-19 and multiple myeloma. All participating patients have filled out a HealthTree profile by contributing their de-identified health data and answered survey questions related to their outcomes during the COVID-19 pandemic.

The aim of the study is to help patients and physicians use real data to drive future medical decisions.

The study was first announced on April 16, 2020. The anonymous answers will be aggregated and analyzed by myeloma researchers to identify recommendations for patients navigating myeloma during the COVID-19 pandemic. Initial study results will be available in July, and more extensive results will be published in December.

Table of Contents

YOU MAY BE INTERESTED IN

By the end of 2022, Toni Monteiro had no fight left in her. She had been battling a rare blood cancer for three years. Her husband had just died. She was at risk of being evicted from her Washington, DC, apartment. Also, her heart was failing. “You’re really under stress,” Monteiro recalls her physician saying. ...

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.

Login